United States Government Publishing Office publisher pbl distributor dst United States Congress Senate author aut Government Organization text government publication eng BILLS To amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy.;Expedited Access to Biosimilars Act;S. 1414 (IS) Bills and Statutes 119_cong_bills legislative 2025-05-01 U.S. Government Publishing Office 2025-04-10 monographic deposited born digital 4 p. Y 1.6: Y 1.4/1: P0b002ee1d2394910 https://www.govinfo.gov/app/details/BILLS-119s1414is S. 1414 021-610-00252-9 000501532 000325576 Congressional bills Senate bills f:s1414_is.txt https://www.govinfo.gov/app/details/BILLS-119s1414is https://www.govinfo.gov/content/pkg/BILLS-119s1414is/html/BILLS-119s1414is.htm https://www.govinfo.gov/content/pkg/BILLS-119s1414is/pdf/BILLS-119s1414is.pdf https://www.govinfo.gov/content/pkg/BILLS-119s1414is/xml/BILLS-119s1414is.xml fdlp DGPO 2025-05-01 2025-05-02 BILLS-119s1414is machine generated eng Rand Paul United States Senate sponsor spn United States Congress Member United States Congress Senate Committee on Health, Education, Labor, and Pensions associated name asn Title 42 Section 262(k) Title 42 Section 262(k)(2)(A) 42 U.S.C. 262(k) 42 U.S.C. 262(k)(2)(A) s BILLS-119s1414is 119 1 SENATE SENATE 1414 is is Expedited Access to Biosimilars Act To amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy. Mr. Paul introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions Committee on Health, Education, Labor, and Pensions Health, Education, Labor, and Pensions Mr. Paul Rand Paul Paul, Rand false false